Dermatologic Therapy最新文献

{"title":"Effects of Water Bathing on Atopic Dermatitis Are Determined by the Constituents in the Water","authors":"Dongyun Lei,&nbsp;Jiechen Zhang,&nbsp;Bijun Xia,&nbsp;Tingting Zhu,&nbsp;Lin Li,&nbsp;Canyi Gong,&nbsp;Litao Zhang,&nbsp;Mao-Qiang Man","doi":"10.1155/dth/3695790","DOIUrl":"https://doi.org/10.1155/dth/3695790","url":null,"abstract":"<div>\u0000 <p>Atopic dermatitis (AD) is a common skin disorder. Although a wide range of therapeutic regimens are available, they have some limitations, including high medical costs. However, evidence suggests that adjuvant regimens such as water bathing are inexpensive and effective approaches for the management of AD. Bathing with either tap water or seawater alone can improve AD symptoms and signs. Combination of water bathing with topic emollient or corticosteroids can synergically alleviate AD. The underlying mechanisms by which water bathing benefits AD include improvements in epidermal function, inhibition of mast cell and Langerhans cell function, reductions in serine protease expression and activity, inhibition of cytokine expression, and upregulation of expression levels of antioxidant enzymes, as well as antimicrobial peptides. In this review, we summarize the effects of water bathing on AD in both humans and murine models as well as the underlying mechanisms.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3695790","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143818507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Strategies and Decision-Making to Optimize Psoriasis Treatment: A French National Survey Based on Virtual Case Vignettes","authors":"Nathalie Quiles-Tsimaratos,&nbsp;Nicole Jouan,&nbsp;Annie Vermersch-Langlin,&nbsp;Anne-Bénédicte Duval-Modeste,&nbsp;Cristèle Nicolas,&nbsp;Caroline Lislaud,&nbsp;Baptiste Roux,&nbsp;Emmanuel Mahé","doi":"10.1155/dth/7294541","DOIUrl":"https://doi.org/10.1155/dth/7294541","url":null,"abstract":"<div>\u0000 <p>Despite current treatments for psoriasis, effective disease control remains challenging for physicians. Current recommendations provide information on when treatment should be optimized, but providing guidance on how to optimize treatments in real-word practice is complex. To examine the decision-making practices of dermatologists when optimizing the management of mild or moderate-to-severe psoriasis, we conducted a nationwide, virtual case vignette-based survey among French dermatologists. Participants reviewed four case vignettes. Data on management suggestions from the dermatologists were collected using questionnaires embedded in the case vignettes. Ninety dermatologists reviewed 356 virtual case vignettes. Of these, 99.4% contained a randomly generated profile describing a virtual psoriasis patient who had responded to current therapy but required treatment optimization, and 23.0% involved mild psoriasis treated with topical treatments, 77.0% involved moderate-to-severe psoriasis treated by conventional systemics or biologics, 59.9% involved psoriasis that had moderate or severe-to-very severe impact on HRQoL, 48.6% had joint involvement, and 58.7% had persistent skin lesions. For virtual patients with mild psoriasis involving topical treatments alone (<i>n</i> = 82), the dermatologists suggested switching or modifying the treatment in 81.7% of cases, most commonly by initiating conventional oral systemic therapy. For virtual cases with moderate-to severe psoriasis involving conventional oral systemic therapies (<i>N</i> = 90), the most common suggestion was to switch treatment (54.4% of cases), most notably to biologic therapy. Switching to a second-line or subsequent-line biologic was the most common suggestion for virtual cases already undergoing biologic therapy. Overall, modifying the existing treatment was suggested for 31.5% of the virtual cases, most notably by introducing new treatment combinations (biologics with conventional systemic and/or topical treatments). Impact on HRQoL, joint involvement, and persistent skin lesions were identified as factors influencing dermatologist decision-making (<i>p</i> &lt; 0.001). Our findings provide valuable insights into the current decision-making practices of French dermatologists when optimizing the management of mild or moderate-to-severe psoriasis.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7294541","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database","authors":"Zi-Yue Dong,&nbsp;Ming-Jie He,&nbsp;Yuan Hu","doi":"10.1155/dth/9922950","DOIUrl":"https://doi.org/10.1155/dth/9922950","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Immune checkpoint inhibitors (ICIs) revolutionize cancer therapy but frequently cause immune-related adverse events (irAEs), with autoimmune skin diseases (ASDs) being significant toxicities requiring careful management.</p>\u0000 <p><b>Objective:</b> This study explores the association between ICIs and 10 common ASDs using the FAERS database, aiming to identify risk profiles, time-to-onset patterns, and clinical implications.</p>\u0000 <p><b>Methods:</b> A retrospective pharmacovigilance analysis of FAERS data (2011Q1–2024Q4) was conducted, focusing on reports involving seven ICIs. Disproportionality algorithms (ROR, PRR, BCPNN, and MGPS) and statistical methods, including Kaplan–Meier and Weibull models, were employed to evaluate ASD risk and onset patterns.</p>\u0000 <p><b>Results:</b> Among 1670 cases, bullous pemphigoid (BP) showed the strongest association, particularly with PD-1/PD-L1 inhibitors, and other prominent ASDs, including vitiligo, psoriasiform dermatitis, lichen planus, and dermatomyositis. Scleroderma, Henoch–Schönlein purpura, pemphigus, alopecia areata, and systemic lupus erythematosus exhibited limited or inconsistent signals across different ICIs. The median time-to-onset was 143 days, with early onset linked to ipilimumab and atezolizumab. Reports predominantly involved males (62.8%) and patients ≥ 65 years old (51.7%), with the United States and Japan contributing most cases.</p>\u0000 <p><b>Conclusions:</b> BP, vitiligo, psoriasiform dermatitis, lichen planus, and dermatomyositis are key irAEs of ICIs, requiring vigilant monitoring and individualized management strategies. Limitations include biases in spontaneous reporting and underrepresentation of newer ICIs.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9922950","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143801518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemotherapy for Multiple Nonmelanoma Skin Tumors in Immunosuppressed Patients: A Prospective Cohort Analysis","authors":"Petra Rózsa,&nbsp;Benjamin Tamás Papp,&nbsp;Edit Szederkényi,&nbsp;Gábor Vass,&nbsp;Csilla Hánis,&nbsp;Ildikó Csányi,&nbsp;Henriette Ócsai,&nbsp;Eszter Baltás,&nbsp;Judit Oláh,&nbsp;Lajos Kemény,&nbsp;Rolland Gyulai,&nbsp;Erika Kis","doi":"10.1155/dth/7037657","DOIUrl":"https://doi.org/10.1155/dth/7037657","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Immunosuppressed patients face a significantly higher risk of developing malignant skin tumors compared to the general population, often presenting with numerous, rapidly growing, and aggressive lesions. It can be particularly challenging to treat these tumors, especially in the head and neck region. Electrochemotherapy (ECT) emerges as a viable option for treating multiple tumors simultaneously. This study aims to compare the efficacy, toxicity, and impacts on the quality of life of ECT of nonmelanoma skin cancers (NMSCs) in immunosuppressed patients and nonimmunosuppressed patients.</p>\u0000 <p><b>Materials and Methods:</b> A total of 156 tumors (82 target lesions) in 14 immunosuppressed patients and 183 tumors (157 target lesions) in 30 nonimmunosuppressed patients were treated with ECT using intravenous bleomycin according to the European Standard Operating Procedures of ECT (ESOPE) guidelines. Patients were monitored for at least 6 months. A prospective cohort analysis was carried out to compare tumor response, side effects, and quality of life in the two groups.</p>\u0000 <p><b>Results:</b> 3 months after ECT, nonimmunosuppressed patients showed a significantly higher tumor response rate (<i>p</i> = 0.001). After 6 months, a statistically significant difference was not observed between the two groups regarding tumor response. After 3 and 6 months, there was no difference in toxicity, pain, and EQ-VAS values.</p>\u0000 <p><b>Conclusions:</b> Our results suggest that the effectiveness and safety of ECT for treating NMSCs in immunosuppressed patients seems to be comparable to the nonimmunosuppressed patients. The emphasis on prevention, adopting a multidisciplinary approach, and optimizing immunosuppression are crucial to improving the care and management of this patient cohort.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7037657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143770008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of 1064-nm Nanosecond Laser Modalities (Q-NDY and MDF Handpieces) for Treating Hand Skin Aging: A Prospective Randomized Controlled Trial","authors":"Jiying Dong,&nbsp;Shanshan Yao,&nbsp;Shen Wang,&nbsp;Min Yan,&nbsp;Nan Lu,&nbsp;Wenjuan Zhang,&nbsp;Min Yao","doi":"10.1155/dth/4994054","DOIUrl":"https://doi.org/10.1155/dth/4994054","url":null,"abstract":"<div>\u0000 <p><b>Background and Objectives:</b> Hand aging is complex, and while laser treatments effectively address pigmentation, their precise impact on skin thickness and wrinkles remains unclear. This study evaluates the effects of two 1064-nm nanosecond laser modalities (Q-switched Nd:YAG laser (Q-NDY) and multidepth fractional laser (MDF)) on hand skin rejuvenation and safety.</p>\u0000 <p><b>Materials and Methods:</b> A randomized controlled trial involving 20 patients with hand aging signs was conducted. Participants were randomized to the Q-NDY or MDF group, receiving three treatments at four-week intervals, followed by a three-month follow-up. Outcomes were evaluated by two independent plastic surgeons using an observer-reported scale. Skin physiology (thickness, melanin, and erythema indices) was measured, and patient satisfaction was assessed using the patient satisfaction scale (PSS).</p>\u0000 <p><b>Results:</b> Both modalities improved pigmentation and reduced wrinkles. The MDF group showed significantly greater improvement in fine wrinkles (<i>p</i> = 0.0086) and skin texture (<i>p</i> = 0.0209) and a significant increase in skin thickness (<i>p</i> &lt; 0.01), whereas the Q-NDY group did not. Melanin and erythema indices decreased significantly by week 20, with a greater reduction in erythema in the MDF group (<i>p</i> = 0.021). Overall satisfaction was 75% for Q-NDY and 90% for MDF.</p>\u0000 <p><b>Conclusion:</b> Both 1064-nm nanosecond laser modalities rejuvenate hand skin. The MDF mode showed superior outcomes in wrinkle reduction, skin texture, and thickness, offering a safe and effective treatment option for hand rejuvenation.</p>\u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: MR-31-23-013044</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4994054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study","authors":"Tiago Torres,&nbsp;Antonio Martorell,&nbsp;Paulo Leal Filipe,&nbsp;Caridad Soria,&nbsp;Fernando Mota,&nbsp;José Pardo,&nbsp;Miquel Ribera,&nbsp;Ricardo Ruiz-Villaverde","doi":"10.1155/dth/7529636","DOIUrl":"https://doi.org/10.1155/dth/7529636","url":null,"abstract":"<div>\u0000 <p><b>Background and Aim:</b> Quality of life (QoL) of psoriasis patients treated with calcipotriol/betamethasone dipropionate (Cal/BD) foam has not been thoroughly evaluated in real-world settings. This study evaluated the change in plaque psoriasis patients’ QoL after 4 weeks of first treatment with Cal/BD foam and after 6 months under daily practice conditions.</p>\u0000 <p><b>Methods:</b> A prospective, noninterventional study evaluated QoL, treatment adherence, satisfaction, and efficacy through the dermatology life quality index (DLQI), the Morisky-Green scale, the treatment satisfaction questionnaire for medication (TSQM-9), and the change in the body surface area (BSA) with plaque psoriasis, among others.</p>\u0000 <p><b>Results:</b> A total of 172 adult patients with plaque psoriasis were included. After 4 weeks of treatment, 53.5% of patients had a DLQI score ≤ 1. Mean absolute change in the DLQI score from baseline was −4.2 after 4 weeks of treatment and −4.0 after the 6-month follow-up (<i>p</i> &lt; 0.0001). Improvement in the BSA was statistically significant after the first treatment period and after the 6-month follow-up with a mean reduction of 2.4% and 2.6%, respectively (<i>p</i> &lt; 0.0001). Mean absolute change in global satisfaction between the end of the 4-week treatment period and the 6-month follow-up was −4.3 (<i>p</i> = 0.0049). In total, 41% of patients were compliant after the first treatment period, and 55.3% were moderately compliant. Higher patient treatment satisfaction was moderately correlated with lower DLQI scores after 4 weeks (<i>r</i> = −0.527; <i>p</i> &lt; 0.0001). Statistically significant differences between DLQI groups were found in the BSA: patients with DLQI ≤ 1 after 4 weeks of treatment had a lower BSA than patients with DLQI &gt; 1 (1.3 ± 1.8 vs. 2.8 ± 2.7, respectively; <i>p</i> &lt; 0.0001).</p>\u0000 <p><b>Conclusion:</b> After 4 weeks of treatment, daily use of Cal/BD foam in plaque psoriasis patients resulted in an improvement in QoL that was related to an improvement in both satisfaction and efficacy.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7529636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Survival in the Treatment of Mucosal Lichen Planus: A Retrospective Multicenter Study","authors":"Neda Cramer,&nbsp;Daniel Kromer,&nbsp;Julia M. Bootsveld,&nbsp;Sascha Gerdes,&nbsp;Petra Staubach-Renz,&nbsp;Katharina Assaf,&nbsp;Dagmar Wilsmann-Theis,&nbsp;Claudia Günther,&nbsp;Christian Kromer,&nbsp;Rotraut Mössner","doi":"10.1155/dth/8752339","DOIUrl":"https://doi.org/10.1155/dth/8752339","url":null,"abstract":"<div>\u0000 <p><b>Background and Objectives:</b> Mucosal lichen planus (LP) is a rare chronic inflammatory skin disease. Its treatment is difficult and comparative data on the sustainability of different drugs are lacking. We aimed to retrospectively assess patient and disease characteristics and analyze drug survival rates in the treatment of mucosal LP under real-world conditions.</p>\u0000 <p><b>Patients and Methods:</b> Our retrospective study included patients with mucosal LP treated systemically in the dermatology departments of five German University Medical Centers between 01/2005 and 03/2022. Patient and disease characteristics and treatment responses were evaluated. Drug survival from systemic therapies was assessed by Kaplan–Meier analysis and multivariate regression.</p>\u0000 <p><b>Results:</b> Overall, 281 patients with a total of 407 treatment courses were identified. The overall median drug survival was 5.0 months (conventional drugs: 5.0 months vs. novel drugs [biologicals and Janus kinase inhibitors]: 17.0 months, <i>p</i> = 0.029). Among conventional drugs, median drug survival was numerically the highest for methotrexate (13.0 months), followed by mycophenolate mofetil (12.0 months); hydroxychloroquine (9.0 months); acitretin and cyclosporine (6.0 months each); azathioprine, dapsone, and other retinoids (5.0 months each); and finally glucocorticoids (2.0 months). Among novel drugs, median drug survival was numerically the highest in TNF-α blockers and IL-17 antagonists (median: 21.0 and 17.0 months, respectively), while median drug survival for Janus kinase inhibitors has not yet been reached. Altogether, the outcomes were documented in 68.6% of cases, with excellent (33.5%), partial (34.5%) or nonresponse (32.0%) in one-third of cases each. The group of novel therapies comprising biologicals and Janus kinase inhibitors was significantly more effective than the group of conventional drugs (excellent response: 66.7%, 8/12 vs. 32.1%, 83/258; <i>P</i> = 0.013, <i>χ</i>²-test).</p>\u0000 <p><b>Conclusions:</b> In addition to glucocorticoids, cyclosporine, mycophenolate mofetil, and methotrexate (plus hydroxychloroquine), biologicals and Janus kinase inhibitors in particular seem to be therapeutic options for the treatment of mucosal LP, which is worth investigating further.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8752339","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Minimally Invasive Surgical Procedure for the Treatment of Steatocystoma Multiplex","authors":"Nan Zhang,&nbsp;Zepeng Li,&nbsp;Zhongke Xue,&nbsp;Weiling Wang,&nbsp;Yan Zheng,&nbsp;Wenwei Zhao","doi":"10.1155/dth/8623135","DOIUrl":"https://doi.org/10.1155/dth/8623135","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Steatocystoma multiplex (SM) is an asymptomatic benign skin lesion, characterized by multiple sebum-containing dermal cysts.</p>\u0000 <p><b>Objectives:</b> In this study, we report a novel surgical procedure of removal of the cysts followed by a 5-fluorouracil injection to fulfill the cosmetic needs of patients with SM.</p>\u0000 <p><b>Methods:</b> From January 2023 to January 2024, 35 patients with SM, 2 of whom showed septic steatocystoma, were surgically treated with the novel surgical method in the First Affiliated Hospital of Xi’an Jiaotong University. All procedures were performed in the outpatient operating room. Patients were in close follow-up for postoperative data, with the most recent follow-up until March 2024.</p>\u0000 <p><b>Results:</b> The surgical intervention is completed within a maximum duration of 40 min for each patient, and all 35 patients with SM exhibited complete postoperative wound healing with no relapse, no cicatrization, and limited hyperpigmentation in mere 4 patients (all within 3 months postoperatively), indicating a favorable overall cosmetic outcome at the latest follow-up in March 2024.</p>\u0000 <p><b>Conclusion:</b> Surgical removal of the cysts with subsequent 5-fluorouracil injection is a promising and novel operative procedure for SM which is minimally invasive, fulfills the cosmetic needs of the patients, and leads to no recurrence in any case.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8623135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Tofacitinib in Patients With Refractory Prurigo Nodularis: A 16-Week, Single-Center, Prospective, Observational Pilot Study","authors":"Ru Dai,&nbsp;Chao-Cheng Chi,&nbsp;Yuchen Lou,&nbsp;I-Jung Hsieh,&nbsp;Xiao-Yong Man","doi":"10.1155/dth/8988947","DOIUrl":"https://doi.org/10.1155/dth/8988947","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> The current management for prurigo nodularis (PN) is challenging. Tofacitinib may emerge as a promising treatment for PN.</p>\u0000 <p><b>Aim:</b> This study aimed to assess the efficacy and safety of tofacitinib in treating refractory PN.</p>\u0000 <p><b>Design and methods:</b> A 16-week prospective observational pilot study was conducted in patients with moderate-to-severe refractory PN. The enrolled patients received oral tofacitinib. The primary endpoints included improvement in pruritus and quality of life, as measured by investigator’s global assessment (IGA), prurigo activity score (PAS), visual analog scale (VAS), numeric rating scale (NRS), verbal rating scale (VRS), Dermatology Life Quality Index (DLQI), and Itchy Specific Quality of Life (Itchy QoL) at week 12. Secondary endpoints were the proportion of patients with a ≥ 4-point reduction in Worst Itch-Numeric Rating Scale (WI-NRS) from baseline at week 12 and week 16. Safety assessments were conducted through week 16. Besides, historical controls, mixed-effects model (MMRM), and post-hoc analyses were performed to evaluate the efficacy of tofacitinib.</p>\u0000 <p><b>Results:</b> Twenty-four PN patients included demonstrated clinical improvement in terms of skin lesions, pruritus, and quality of life. IGA, PAS items, VAS, NRS, VRS, DLQI, and Itchy QoL significantly improved from the baseline to 12 weeks of tofacitinib treatment (<i>p</i> &lt; 0.05 for all). However, the response to tofacitinib became less pronounced at week 16, with reduced improvement in skin lesions, itch, and quality of life compared to that at week 12. The percentage of patients experiencing a ≥ 4-point WI-NRS reduction decreased from 75% at week 12% to 66.67% at week 16. The results of historical controls, MMRM model, and post hoc analyses supported the clinical efficacy of tofacitinib in PN, with baseline NRS_24h,worst appearing to be a potentially clinical feature impacting treatment efficacy. No severe adverse events were reported up until the end of the study period.</p>\u0000 <p><b>Conclusions:</b> Tofacitinib demonstrates effectiveness in reducing itch and skin infiltration in patients with moderate-to-severe PN, whereas its long-term efficacy requires further observation.</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT06201715</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8988947","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alitretinoin for the Treatment of Lichen Amyloidosis: A Retrospective, Observational Study and an In Vitro Study","authors":"Eun Joo Baek,&nbsp;Sun Mee Shin,&nbsp;Seong Jun Kim,&nbsp;Kwang Ho Kim,&nbsp;Kwang Joong Kim,&nbsp;Eun Joo Park","doi":"10.1155/dth/7835429","DOIUrl":"https://doi.org/10.1155/dth/7835429","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Lichen amyloidosis (LA) is the most common form of localized cutaneous amyloidosis, often accompanied by severe pruritus. Treatment options are limited, and alitretinoin, a systemic retinoid, has shown promise in managing refractory cases.</p>\u0000 <p><b>Objective:</b> This study aimed to evaluate the efficacy of alitretinoin in treating LA and its effects on keratinocytes.</p>\u0000 <p><b>Methods:</b> We conducted a retrospective analysis of 13 patients diagnosed with LA treated with alitretinoin. In addition, an in vitro study assessed the impact of alitretinoin on keratinocyte inflammation markers.</p>\u0000 <p><b>Results:</b> Of the 13 patients, 4 (30.77%) achieved complete clearance of lesions, demonstrating excellent improvement. The remaining 9 (69.23%) showed substantial improvement, with almost clear or mild residual lesions. In vitro, alitretinoin significantly decreased levels of IL-33, periostin, CCL5, and PTGES.</p>\u0000 <p><b>Conclusion:</b> Alitretinoin demonstrated effectiveness in treating LA, with favorable outcomes in both clinical and in vitro settings. These findings support alitretinoin as a viable treatment option for LA.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7835429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}